WATERS CORP /DE/ (WAT)
Data as of , from SEC Form 4 filings.
See up to 3 months of WAT. The 7-day demo opens the 1M and 3M ranges and puts WAT on your watchlist.
Start 7-day demoLatest WAT insider trades
- Christopher A. Kuebler - DirectorOpen-market sale$1.44M
Wei Jiang - DirectorOpen-market purchase$145K
About WATERS CORP /DE/ (WAT)
The SEC lists WATERS CORP /DE/ under CIK 0001000697, in laboratory analytical instruments. We track it alongside the rest of the Health Care sector.
WAT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 3,626 | $1.44M |
| Grant or award | 2 | 114.82 | |
| Option exercise | 2 | 7,252 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
WAT insider transactions (Form 4)
4655 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Heather Knight - Director | Grant or award | Common Stock | 57.41 footnote F1 | $0.00 | - | |
| ||||||
| Wei Jiang - Director | Grant or award | Common Stock | 57.41 footnote F1 | $0.00 | - | |
| ||||||
| Christopher A. Kuebler - Director | Option exercise | Common Stock | 3,626 | $136.43 | $495K | |
| Christopher A. Kuebler - Director | Open-market sale | Common Stock | 3,626 | $397.94 | $1.44M | |
| Christopher A. Kuebler - Director | Option exercise | Stock Option (Right to Buy) | 3,626 | $0.00 | - | |
| Heather Knight - Director | Grant or award | Common Stock | 63.03 footnote F1 | $0.00 | - | |
| ||||||
| Wei Jiang - Director | Grant or award | Common Stock | 67.42 footnote F1 | $0.00 | - | |
| ||||||
| Robert L. Carpio III - Officer | Tax withholding / forfeiture | Common Stock | 189 footnote F1 | $369.18 | $70K | |
| ||||||
| Amol Chaubal - Officer | Tax withholding / forfeiture | Common Stock | 239 footnote F1 | $352.21 | $84K | |
| ||||||
| Jianqing Bennett - Officer | Tax withholding / forfeiture | Common Stock | 302 footnote F1 | $304.09 | $92K | |
| ||||||
| Wei Jiang - Director | Grant or award | Common Stock | 64.06 footnote F1 | $0.00 | - | |
| ||||||
| Heather Knight - Director | Grant or award | Common Stock | 68.44 footnote F1 | $0.00 | - | |
| ||||||
| Wei Jiang - Director | Open-market purchase | Common Stock | 500 | $289.46 | $145K | |
| Richard H. Fearon - Director | Open-market purchase | Common Stock | 1,000 | $306.34 footnote F1 | $306K | |
| ||||||
 Udit Batra - Officer | Tax withholding / forfeiture | Common Stock | 3,417 footnote F1 | $307.23 | $1.05M | |
| ||||||
| Amol Chaubal - Officer | Tax withholding / forfeiture | Common Stock | 709 footnote F1 | $307.23 | $218K | |
| ||||||
| Jianqing Bennett - Officer | Tax withholding / forfeiture | Common Stock | 410 footnote F1 | $307.23 | $126K | |
| ||||||
| Robert L. Carpio III - Officer | Grant or award | Common Stock | 997 footnote F1 | $0.00 | - | |
| Robert L. Carpio III - Officer | Grant or award | Stock Option (Right to Buy) | 4,884 | $0.00 | - | |
| ||||||
| Jianqing Bennett - Officer | Grant or award | Common Stock | 986 footnote F1 | $0.00 | - | |
| Jianqing Bennett - Officer | Grant or award | Stock Option (Right to Buy) | 4,826 | $0.00 | - | |
| ||||||
| Amol Chaubal - Officer | Grant or award | Common Stock | 1,455 footnote F1 | $0.00 | - | |
| Amol Chaubal - Officer | Grant or award | Stock Option (Right to Buy) | 7,125 | $0.00 | - | |
| ||||||
| Udit Batra - Officer | Grant or award | Common Stock | 5,165 footnote F1 | $0.00 | - | |
| Udit Batra - Officer | Grant or award | Stock Option (Right to Buy) | 25,283 | $0.00 | - | |
| ||||||
| Mark Vergnano - Director | Grant or award | Common Stock | 23 footnote F1 | $0.00 | - | |
| Mark Vergnano - Director | Grant or award | Stock Option (Right to Buy) | 57 footnote F2 | $0.00 | - | |
| ||||||
| Christopher A. Kuebler - Director | Grant or award | Common Stock | 23 footnote F1 | $0.00 | - | |
| Christopher A. Kuebler - Director | Grant or award | Stock Option (Right to Buy) | 57 footnote F2 | $0.00 | - | |
| ||||||
| Heather Knight - Director | Grant or award | Common Stock | 23 footnote F1 | $0.00 | - | |
| Heather Knight - Director | Grant or award | Stock Option (Right to Buy) | 57 footnote F2 | $0.00 | - | |
| ||||||
| Wei Jiang - Director | Grant or award | Common Stock | 23 footnote F1 | $0.00 | - | |
| Wei Jiang - Director | Grant or award | Stock Option (Right to Buy) | 57 footnote F2 | $0.00 | - | |
| ||||||
| Pearl S. Huang - Director | Grant or award | Common Stock | 23 footnote F1 | $0.00 | - | |
| Pearl S. Huang - Director | Grant or award | Stock Option (Right to Buy) | 57 footnote F2 | $0.00 | - | |
| ||||||
| Claire Fraser - Director | Grant or award | Common Stock | 358 footnote F1 | $0.00 | - | |
| Claire Fraser - Director | Grant or award | Stock Option (Right to Buy) | 877 footnote F2 | $0.00 | - | |
| ||||||
| Richard H. Fearon - Director | Grant or award | Common Stock | 23 footnote F1 | $0.00 | - | |
| Richard H. Fearon - Director | Grant or award | Stock Option (Right to Buy) | 57 footnote F2 | $0.00 | - | |
| ||||||
| Daniel J. Brennan - Director | Grant or award | Common Stock | 23 footnote F1 | $0.00 | - | |
| Daniel J. Brennan - Director | Grant or award | Stock Option (Right to Buy) | 57 footnote F2 | $0.00 | - | |
| ||||||
| Linda Baddour - Director | Grant or award | Common Stock | 23 footnote F1 | $0.00 | - | |
| Linda Baddour - Director | Grant or award | Stock Option (Right to Buy) | 57 footnote F2 | $0.00 | - | |
| ||||||
 Flemming Ornskov - Director | Grant or award | Common Stock | 336 footnote F1 | $0.00 | - | |
| Flemming Ornskov - Director | Grant or award | Stock Option (Right to Buy) | 57 footnote F2 | $0.00 | - | |
| ||||||
| Robert L. Carpio III - Officer | Tax withholding / forfeiture | Common Stock | 38 footnote F1 | $376.89 | $14K | |
| ||||||
Item 5.02, 8.01
Item 2.02, 9.01
Item 5.07
Item 2.02, 9.01
Recent WAT Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| KUEBLER CHRISTOPHER A | Director | 3,626 | $1.44M | View on EDGAR |
Stock trades in WAT disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Kevin HernRepublican, OK-01 | Sale |
WAT insider trading FAQ
What is the latest insider trade for WAT?
WATERS CORP /DE/ (WAT) had 3 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for WAT runs to 55 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying WAT stock?
No insider purchases of WAT were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling WAT stock?
1 insider sale of WAT was filed in the last 90 days, totaling $1.44M.
Where can I see WAT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects WAT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Heather Knight view on EDGAR
- - Wei Jiang view on EDGAR
- - Christopher A. Kuebler view on EDGAR
- - Heather Knight view on EDGAR
- - Wei Jiang view on EDGAR
- - Robert L. Carpio III view on EDGAR
- - Amol Chaubal view on EDGAR
- - Jianqing Bennett view on EDGAR
- - Wei Jiang view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where WAT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow WAT with a 7-day demo
- WAT on your watchlist
- Every WAT Form 4 filing on record
- Up to 3 months of WAT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
